News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
697,339 Results
Type
Article (41468)
Company Profile (294)
Press Release (655577)
Section
Business (209647)
Career Advice (2060)
Deals (36549)
Drug Delivery (89)
Drug Development (82543)
Employer Resources (170)
FDA (16375)
Job Trends (15329)
News (354287)
Policy (33781)
Tag
Academia (2572)
Africa (774)
Alliances (50931)
Alzheimer's disease (1152)
Approvals (16312)
Arizona (176)
Artificial intelligence (75)
Asia (39591)
Australia (6311)
Bankruptcy (360)
Best Places to Work (11364)
Biosimilars (66)
Biotechnology (187)
C2C Services and Suppliers (79730)
California (1660)
Canada (864)
Cancer (348)
Career advice (1722)
Cell therapy (104)
China (122)
Clinical research (64488)
Collaboration (114)
Colorado (67)
Compensation (61)
Connecticut (67)
COVID-19 (2549)
Cystic fibrosis (74)
Data (170)
Diabetes (70)
Diagnostics (6032)
Drug pricing (69)
Earnings (85298)
Employer resources (145)
Europe (84052)
Events (110358)
Executive appointments (115)
FDA (16562)
Florida (230)
Funding (110)
Gene therapy (89)
GLP-1 (528)
Government (4400)
Healthcare (18762)
Hotbed/Location (489749)
Illinois (244)
Indiana (142)
Infectious disease (2573)
Inflammatory bowel disease (90)
Interviews (316)
IPO (16450)
Job creations (4045)
Job search strategy (1482)
Kansas (93)
Layoffs (410)
Legal (8290)
Lung cancer (74)
Manufacturing (80)
Maryland (362)
Massachusetts (1393)
Medical device (13103)
Medtech (13106)
Mergers & acquisitions (19917)
Metabolic disorders (232)
Michigan (119)
Minnesota (205)
Neuroscience (1284)
New Jersey (513)
New York (522)
NextGen Class of 2024 (6603)
Non-profit (4499)
North Carolina (587)
Northern California (749)
Obesity (143)
Ohio (98)
Opinion (191)
Patents (66)
Pennsylvania (541)
People (57688)
Pharmaceutical (84)
Phase I (19890)
Phase II (28376)
Phase III (21340)
Pipeline (100)
Postmarket research (2635)
Preclinical (8479)
Press Release (68)
Rare diseases (121)
Real estate (6230)
Recruiting (65)
Regulatory (21983)
Research institute (2350)
Resumes & cover letters (354)
South America (1151)
Southern California (668)
Startups (3705)
Texas (204)
United States (7832)
Vaccines (468)
Washington State (240)
Weight loss (127)
Date
Today (6)
Last 7 days (583)
Last 30 days (2054)
Last 365 days (37756)
2024 (25422)
2023 (40628)
2022 (51797)
2021 (56332)
2020 (54795)
2019 (47402)
2018 (35773)
2017 (33140)
2016 (32663)
2015 (38616)
2014 (32516)
2013 (27632)
2012 (29729)
2011 (30488)
2010 (28497)
697,339 Results for "vanda pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Future Pak Issues Enhanced and Final Proposal to Acquire Vanda Pharmaceuticals Inc.
Future Pak, LLC and its affiliates announced that it has submitted a final attempt to engage with Vanda Pharmaceuticals Inc. in a good faith effort to acquire all outstanding shares of Vanda.
June 13, 2024
·
4 min read
BioCapital
Vanda Pharmaceuticals Announces Presentations at SLEEP 2024
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at SLEEP 2024, to be held in Houston, TX from June 1 through June 5, 2024.
May 29, 2024
·
1 min read
Deals
Cycle Pharmaceuticals Announces All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per Share
Cycle Pharmaceuticals Ltd today confirmed that it made a proposal to the Board of Directors of Vanda Pharmaceuticals, Inc. (“Vanda”) (NASDAQ: VNDA) on May 24, 2024 to acquire 100% of Vanda’s issued and outstanding shares for a cash consideration of $8.00 per Vanda share, representing a total cash consideration of $466 million.
June 6, 2024
·
5 min read
BioCapital
Vanda Pharmaceuticals Announces Participation in the Jefferies 2024 Global Healthcare Conference
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the Jefferies 2024 Global Healthcare Conference in New York City on Thursday, June 6, 2024.
May 30, 2024
·
1 min read
BioCapital
Vanda Pharmaceuticals Announces Completion of Transfer of FDA Marketing Authorization for PONVORY®
Vanda Pharmaceuticals Inc. today announced that ownership of the U.S. New Drug Application and Investigational New Drug Applications for PONVORY ® (ponesimod) has been transferred to Vanda from a Johnson & Johnson Company, which now fully allows Vanda to commercialize PONVORY ® in the U.S.
May 30, 2024
·
5 min read
Deals
Vanda Pharmaceuticals Board of Directors Determines that Recent Unsolicited Takeover Proposals Are Not in the Best Interests of the Company and its Shareholders
Vanda Pharmaceuticals Inc. announced that the Company’s Board of Directors has determined that the unsolicited proposal from Cycle Group Holdings Ltd to acquire Vanda for $8.00 per share in cash and the revised unsolicited proposal from Future Pak, LLC to acquire Vanda for $8.50-$9.00 per share in cash plus certain Contingent Value Rights both substantially undervalue Vanda and are not in the best interests of the Company and its shareholders.
June 19, 2024
·
3 min read
Business
Vanda Pharmaceuticals Reports First Quarter 2024 Financial Results
Vanda Pharmaceuticals Inc. announced financial and operational results for the first quarter ended March 31, 2024.
May 8, 2024
·
16 min read
Deals
Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak
Vanda Pharmaceuticals Inc. (“Vanda” or the “Company”) (Nasdaq: VNDA) today confirmed that it has received a revised unsolicited proposal from Future Pak, LLC (“Future Pak”) to acquire the Company.
May 7, 2024
·
1 min read
Business
Vanda Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 8, 2024
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2024 on Wednesday, May 8, 2024, after the market closes.
April 30, 2024
·
1 min read
Policy
Vanda Pharmaceuticals Reacts to U.S. Supreme Court’s Denial of its Petition in HETLIOZ® ANDA Litigation
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Supreme Court denied Vanda’s petition for a writ of certiorari in its HETLIOZ ® Abbreviated New Drug Application litigation against Teva Pharmaceuticals USA , Inc.
April 22, 2024
·
1 min read
1 of 69,734
Next